Single factor analysis showed that age, hypertension, coronary heart disease, left chest wall radiotherapy and anthracene sequential therapy were the risk factors for the cardiotoxicity related to anti-HER2-targeted therapy in early breast cancer (P < 0.05). The gene discussed is ERBB2; the disease is Hypertension.